Skip to main content
Clinical Trials/NCT02420769
NCT02420769
Completed
Not Applicable

Color Doppler of CL and Uterine Artery With Serum Progesterone and CA125 in Threatened Abortion

Nesreen Abdel Fattah Abdullah Shehata1 site in 1 country100 target enrollmentSeptember 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Threatened Abortion
Sponsor
Nesreen Abdel Fattah Abdullah Shehata
Enrollment
100
Locations
1
Primary Endpoint
Viable fetus (According to WHO viable fetus >500 gm or > 20 weeks)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to determine whether assessing color doppler of corpus luteum and uterine artery is useful in predicting patients who will complete pregnancy. The investigators will add to this the usefulness of serum progesterone and CA125 in prediction.

Detailed Description

The introduction of Doppler ultrasound in obstetrics has allowed evaluating hemodynamic characteristics from the first trimester of pregnancy. For example, Kurjak et al.,in one of the first studies using transvaginal pulsed-wave Doppler ultrasound in early pregnancies, identified the uterine arteries in 100% of the patients. The flow blood of the corpus luteum was identified in 75% patients. The measures obtained by Doppler ultrasonography that may have prognostic value to the evolution of pregnancy include uteroplacental blood flow, also known as trophoblastic flow. Jaffe et al. reported that abnormal Doppler findings were associated with a significantly higher prevalence of complicated pregnancies, among women with abnormal Doppler findings, 43% ended in miscarriage, whereas among women with normal findings only 1.4% of women miscarried.Progesterone plays a crucial role in the maintenance of pregnancy. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator called progesterone induced blocking factor (PIBF), which is anti-abortive in mice . Besides inducing secretary changes in the endometrium and supporting early pregnancy, it modulates the maternal immune response to prevent fetal rejection and relaxes the uterine smooth muscles .CA-125, well-known as a tumor marker for epithelial ovarian cancer , is a high molecular weight glycoprotein that is produced not only by ovarian cancer, but also by nonovarian tumors, normal epithelia of the peritoneum, the endometrium, the fallopian tube, and the ovary. Because CA-125 is also produced by the endometrium, some authors suggest that CA-125 can be used as a marker for endometrial receptivity in patients undergoing IVF . Its role as a predictor for pregnancy outcome is controversial .

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
May 2017
Last Updated
8 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Nesreen Abdel Fattah Abdullah Shehata
Responsible Party
Sponsor Investigator
Principal Investigator

Nesreen Abdel Fattah Abdullah Shehata

Assisstant professor of Obstetrics and Gynecology

Beni-Suef University

Eligibility Criteria

Inclusion Criteria

  • patients with pregnancy between 8 to 20 weeks of gestation,
  • who were diagnosed with threatened abortion.

Exclusion Criteria

  • patients with multiple pregnancies,
  • molar pregnancy,
  • ectopic pregnancy,
  • amenorrhea with different etiologies of pregnancy,
  • maternal history of systemic diseases and uterine anatomic abnormalities
  • patients who did not have their outcome data through week 20 of gestation due to relocation.

Outcomes

Primary Outcomes

Viable fetus (According to WHO viable fetus >500 gm or > 20 weeks)

Time Frame: from 20 weeks till 21 weeks gestation

The investigators will assess how many patients in both groups reached viability of fetus. According to WHO viable fetus \>500 gm or \> 20 weeks.

Secondary Outcomes

  • Resistance index of uterine artery and corpus luteum(from 8 weeks till 20 weeks)
  • serum CA125 and progesterone(from 8 weeks till 20 weeks gestation)

Study Sites (1)

Loading locations...

Similar Trials